Last €70.50 EUR
Change Today +0.58 / 0.83%
Volume 3.0
6COP On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:18 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (6COP) Snapshot

Open
€70.52
Previous Close
€69.92
Day High
€70.52
Day Low
€70.02
52 Week High
06/16/14 - €72.60
52 Week Low
10/7/13 - €43.29
Market Cap
31.9B
Average Volume 10 Days
147.4
EPS TTM
--
Shares Outstanding
451.8M
EX-Date
10/3/14
P/E TM
--
Dividend
€1.44
Dividend Yield
1.33%
Current Stock Chart for COVIDIEN PLC (6COP)

covidien plc (6COP) Related Businessweek News

View More BusinessWeek News

covidien plc (6COP) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company’s Medical Devices segment develops, manufactures, and sells endomechanical instruments, such as laparoscopic instruments, surgical staplers, and interventional lung solutions; energy devices, including vessel sealing, electrosurgical, and ablation products and related capital equipment; and soft tissue repair products comprising sutures, mesh, biosurgery products, and hernia mechanical devices. This segment also offers vascular products, such as compression, dialysis, venous insufficiency, thrombectomy, neurovascular, and peripheral vascular products; oximetry and monitoring products, including sensors, monitors, and temperature management products; and airway and ventilation products comprising airway, ventilator, breathing systems, and inhalation therapy products. Its products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. The company’s Medical Supplies segment develops, manufactures, and distributes nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products; medical surgical products, such as operating room supply products related accessories, electrodes, thermometry, and chart paper product lines; SharpSafety products, including needles, syringes, and sharps disposal products; and original equipment manufacturer products. Its products are used primarily in hospitals, surgi-centers, and alternate care facilities, such as homecare and long-term care facilities. The company markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

38,500 Employees
Last Reported Date: 11/21/13

covidien plc (6COP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $783.5K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and General Counsel
Total Annual Compensation: $580.9K
Compensation as of Fiscal Year 2013.

covidien plc (6COP) Key Developments

Covidien Announces Start of Enrollment in Two Neurovascular Clinical Trials

Covidien plc announced the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company's advanced neurovascular solutions. Baptist Medical Center in Jacksonville, Florida, treated the first patient enrolled in the PREMIER Prospective study, an international Investigational Device Exemption (IDE) clinical study to evaluate the Pipeline(TM) embolization device in smaller unruptured intracranial aneurysms. Separately, Baptist Health Lexington in Kentucky, enrolled the first patient in the STRATIS Registry for Endovascular Stroke Devices, which will evaluate the use of all Covidien market-released stroke devices. The PREMIER study will enroll up to 141 patients in 20 global sites and is designed to assess the safety and effectiveness of the Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms (IAs). The STRATIS Registry, a prospective, multi-center, non-randomized, observational registry designed to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with an acute ischemic stroke. Covidien's current endovascular stroke device in the U.S. is the Solitaire(TM) 2 revascularization device.

Covidien plc Recommends First and Final Dividend for Financial Year Ended June 30, 2014

The board of directors of Covidien plc has recommended a first and final dividend of 0.25 cents per share (tax-exempt one-tier) for its financial year ended June 30, 2014, to be paid out on November 19, 2014.

Covidien Opens Advanced Medical Technology Center in Brazil

Covidien plc officially opened its Covidien Center of Innovation Brazil (CCI Brazil), further expanding its educational and research capabilities in a key emerging market. The CCI will help educate clinicians in Brazil and the surrounding region on the latest medical technology, enabling them to more safely and efficiently perform a variety of procedures that can save and improve patients' lives. The Covidien Center of Innovation Brazil in São Paulo features a surgical lab fully equipped for minimally invasive surgeries using electronic and computer simulators as well as silicone models. The CCI in São Paulo is approximately 3,000 square meters and has the capacity to offer 120 courses and educate 2,000 professionals per year. Features include: A surgical lab fully equipped for minimally invasive surgeries using electronic and computer simulators as well as silicone models, A clinical scenario simulation lab equipped with a human patient simulator (computerized mannequin that bleeds and has cardiac arrests and changes in blood pressure, among other critical situations found in an intensive care unit), A laboratory for educating in medical and hospital procedures, with silicone models and equipment for tests and simulations, The only Anatomage touchscreen table in São Paulo. Anatomage is a revolutionary technology that allows the study of the human body's anatomy in a virtual patient, combining CT imaging with the traditional operating room experience and delivering unparalleled anatomical images; A research and development lab to enable health care professionals to directly collaborate with R&D staff, An auditorium that accommodates 160 people and features a multimedia system for transmitting real-time audio and video of health care procedures and training sessions for partner institutions that include the country's most renowned hospitals and universities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6COP:GR €70.50 EUR +0.58

6COP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $237.09 USD -1.67
Baxter International Inc $72.65 USD -2.34
Kimberly-Clark Corp $106.72 USD -0.13
Stryker Corp $83.94 USD -0.12
Tyco International Ltd $44.31 USD -0.14
View Industry Companies
 

Industry Analysis

6COP

Industry Average

Valuation 6COP Industry Range
Price/Earnings 27.7x
Price/Sales 4.0x
Price/Book 4.2x
Price/Cash Flow 27.3x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit www.covidien.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.